GeneDx Accepts Slower Test Growth To Get Paid — Some Orders Cannot Be Reimbursed

Genome collections improved, but management lowered volume expectations and put annual revenue at the bottom of its guidance range.

Share
GeneDx Accepts Slower Test Growth To Get Paid — Some Orders Cannot Be Reimbursed

GeneDx, which uses genetic testing to help diagnose rare diseases, is slowing genome testing to improve payment collection—and some orders cannot be reimbursed even when claims are handled correctly. On Monday's earnings call, Chief Executive Officer Katherine Stueland said the company was choosing paid tests over unrestricted volume growth while raising its adjusted earnings outlook.

The Limits Of Better Paperwork

The most consequential distinction emerged when a Craig-Hallum analyst asked whether GeneDx had been testing patients outside insurers' coverage rules. GeneDx President Mark Gardner confirmed that some tests would produce no reimbursement regardless of how well the company processed the claim.

Gardner said, “we were not actually going to get reimbursed for it.” He also said GeneDx would keep seeking ways to serve those patients, including working through coverage and medical-necessity disputes.

That problem is separate from the larger operational opportunity. GeneDx traced 62% of exome and genome claim denials to administrative or procedural issues. The other 38% involved insurers disputing whether testing was medically necessary or patients falling outside coverage policies.

GeneDx began requiring more insurer documentation before genome testing at the beginning of the third quarter. The change increased cancellations, switches to other tests and delays before laboratory work began. Incoming samples grew 28% from a year earlier, while completed test volume grew 25%.

Gardner told a Piper Sandler analyst that delays of a few days explained most of the difference, rather than permanently lost orders. GeneDx Chief Financial Officer Kevin Feeley said he expected substantially all of that gap eventually to move through testing, although the catch-up would take place over time.

Stueland put the trade-off plainly: “we're putting a premium on paid volume as the goal rather than volume at all costs”.

More Payment, Less Genome Mix

The first results combine better collection with a deliberate shift toward exome testing. Average reimbursement rose 5% from the second quarter to $3,436 per test, from $3,258. Underlying contract rates changed relatively little.

Genome accounted for 26% of outpatient insurance-based test volume, down from 32% in the second quarter. Although genome now has a higher collection percentage, exome has higher average contracted and collected payments. Exome also costs less to perform.

Outpatient genome collections reached 36%, compared with 32% in the previous quarter. Feeley attributed the improvement to early workflow changes. The exome collection rate was approximately 32%, matching the second quarter; exome will be the next focus of the payment overhaul.

Coverage helped, too. Approximately 82% of outpatient genome volume went to insurers with positive coverage policies, versus 67% in the second quarter. Carillon's June expansion covered approximately 56 million lives, and Feeley said plans following that policy contributed to better collections. Medi-Cal contributed much less, with its payment process still difficult to navigate.

Commercial coverage policies applied to 98% of insured lives for exome and 88% for genome. Medicaid covered exome in 37 states and genome in 25, versus 23 states for genome in the second quarter.

Feeley said the company was seeking the appropriate test for each patient, rather than minimizing genome use. Management expects genome's share to grow again as products improve and testing becomes more economical.

Earnings Improve As Volume Expectations Fall

GeneDx reported $123.1 million in third-quarter revenue, including $110.4 million from exome and genome testing, which increased $10 million from the previous quarter. The company completed more than 32,100 exome and genome tests.

Adjusted gross margin reached 72%, compared with 70% in the second quarter and 69% in the first. Adjusted net income was $8.6 million, following near break-even results in the second quarter and an $8.2 million adjusted loss in the first.

Feeley raised full-year adjusted net-income guidance to at least $12 million and adjusted gross-margin guidance to approximately 71%. But he lowered expected exome and genome volume growth to at least 28%, with corresponding test revenue growth of at least 17%. Annual revenue guidance stayed at $475 million–$490 million, with management expecting the low end.

For the fourth quarter, GeneDx expects at least $135 million in total revenue, including $121 million from exome and genome testing on 34,500 completed tests. Feeley forecast average reimbursement of approximately $3,500, adjusted gross margin of at least 71% and approximately $12 million in adjusted net income.

Building Demand While Fixing Collections

The overhaul runs alongside commercial expansion and product development. GeneDx's ExomeDx examines protein-coding DNA; GenomeDx examines the whole genome. Substantially all revenue in 2025 came from diagnostic reports, paid for by insurers, patients and other customers.

Management set priorities in May around profit per test, greater utilization and product capabilities. Outside experts examined payment processes in the second quarter; new leaders validated the plan and designed systems in the third. Feeley outlined technology implementation for the fourth quarter and early 2027, with most improvements expected in 2027 and beyond.

Electronic ordering is already helping. Feeley said orders arriving through Epic showed better documentation and collection results across clinician types. GeneDx is expanding hospital-system integration and has appointed Nicole Masson as Chief Patient Access Officer to develop insurer partnerships and government relations.

Management said its general-pediatrics sales team, which entered the field in February, was already covering its costs. Gardner clarified that general pediatrics could contribute the largest volume-growth increase among individual segments in 2027—not exceed all other segments combined. Prenatal and neonatal intensive-care markets were growing faster than the company overall.

Genome cost per test fell 43% from a year earlier, though it remained substantially higher than exome's. Feeley said GeneDx could cut at least a few hundred dollars more over the next several quarters through lower reagent costs and greater use of artificial intelligence in analysis.

Those savings and improved collections also matter for reimbursement pressure. Approximately 45% of revenue is exposed to PAMA-related laboratory payment changes. Feeley expects those changes to reduce total 2027 revenue by about 5%, but said collection improvements could offset or more than offset that effect.

GeneDx's near-term forecast now pairs slower test growth with higher adjusted earnings. The larger payment-technology rollout is scheduled for the fourth quarter and early 2027; management expects most of its benefits in 2027 and beyond.

Sources

More on GeneDx

All GeneDx (WGS) coverage →